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Danger-associated molecular patterns are released by damaged cells and trigger 
neuroinflammation through activation of non-specific pattern recognition receptors, 
e.g., toll-like receptors (TLRs). Since the role of TLR2 and 4 after traumatic brain injury 
(TBI) is still unclear, we examined the outcome and the expression of pro-inflammatory 
mediators after experimental TBI in Tlr2/4−/− and wild-type (WT) mice. Tlr2/4−/− and 
WT mice were subjected to controlled cortical injury and contusion volume and brain 
edema formation were assessed 24 h thereafter. Expression of inflammatory markers 
in brain tissue was measured by quantitative PCR 15 min, 3 h, 6 h, 12 h, and 24 h 
after controlled cortical impact (CCI). Contusion volume was significantly attenuated 
in Tlr2/4−/− mice (29.7 ± 0.7 mm3 as compared to 33.5 ± 0.8 mm3 in WT; p < 0.05) 
after CCI while brain edema was not affected. Only interleukin (IL)-1β gene expression 
was increased after CCI in the Tlr2/4−/− relative to WT mice. Inducible nitric oxide 
synthetase, TNF, IL-6, and COX-2 were similar in injured WT and Tlr2/4−/− mice, while 
the increase in high-mobility group box 1 was attenuated at 6  h. TLR2 and 4 are 
consequently shown to potentially promote secondary brain injury after experimental 
CCI via neuroinflammation and may therefore represent a novel therapeutic target for 
the treatment of TBI.
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inTrODUcTiOn
Head injury is a major public health problem as it is the most frequent cause of death and disability 
in young adults and therefore produces considerable demands on health services (1). In the patho-
physiology of TBI, primary and secondary brain damage needs to be differentiated. The primary 
tissue damage in the moment of injury occurs due to mechanical forces to the brain parenchyma. 
Nevertheless, a secondary expansion of the primary lesion during the following hours and days 
Abbreviations: BWC, brain water content; CCI, controlled cortical impact; DAMPs, danger-associated molecular patterns; 
dw, dry weight; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HMGB1, high-mobility group box 1; LPS, lipopolysac-
charide; PRR, pattern recognition receptors; TBI, traumatic brain injury; TLR, toll-like receptor; WT, wild-type.
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caused by molecular events initiated by the primary lesion 
leads to propagation of the tissue damage and is an important 
predictor of clinical outcome (2). As a matter of course, we are 
unable to reverse and reduce the instant primary brain damage, 
but delayed secondary loss of tissue is a target for the therapy 
of TBI and its sequelae for many years. Though several clinical 
management strategies to reduce secondary brain damage are 
summarized in guidelines for the treatment of traumatic brain 
injury (TBI), the efforts to directly target molecular events by 
neuroprotective drugs failed so far (3–5).
Recently, neuroinflammation has repeatedly been shown to 
be a major pathophysiological mechanism causing cell death and 
therefore the aggravation of various cerebral pathologies includ-
ing TBI (6, 7). Consequently, its reduction might reduce second-
ary brain damage effectively. Similar to infectious disease-driven 
disturbance of homeostasis, e.g., by tissue debris, trauma induces 
activation of the innate immune system albeit in the absence of 
exogenous compounds. Accordingly, aseptic physical injury to 
the brain has been shown to elicit an acute immune response that 
involves activation of resident microglial cells and increased pro-
duction of pro- and anti-inflammatory cytokines, chemokines, 
and adhesion molecules (8). Non-infectious inflammatory reac-
tions occur toward released danger-associated molecular patterns, 
which alert the innate immune system through various pattern 
recognition receptors (PRRs) (9). Toll-like receptors (TLRs) are a 
family of PRRs involved in the recognition of invariant molecular 
motifs of bacteria, fungi, parasites, and viruses and are highly 
conserved (10). According to recent literature, TLR2 and TLR4, 
expressed by both microglia and astrocytes, recognize the widest 
array of binding partners, such as peptidoglycan, lipoproteins, 
and lipoteichoic acid as well as lipopolysaccharide (LPS) from the 
outer cell wall of Gram-negative bacteria, respectively (11, 12). 
Though they also recognize endogenous danger signals such as 
high-mobility group box 1 (HMGB1) or hyaluronan fragments, 
or heparan sulfate, or fibrinogen, respectively (13–15).
TLR2 and 4 activation in aseptic brain injury induces a 
neuroinflammatory cascade by induction of pro-inflammatory 
cytokines and thereby might induce secondary tissue damage 
(16). Previous studies showed an upregulation of TLR2 and 4 
following experimental ischemic stroke, while genetic deletion 
of TLR2, 4, and 9 attenuated tissue damage (14). In this study, 
we therefore hypothesize that synergistic activation of TLR2 and 
4 may well contribute to post-TBI when using a clinically more 
relevant TBI model. Therefore, we used TLR2 and 4 double-
knockout mice and investigated secondary necrosis growth, 
brain edema formation, and expression of inflammatory markers 
following controlled cortical impact (CCI).
To investigate most pro-inflammatory pathways, interleukin 
(IL)-1β, HMGB1, inducible nitric oxide synthetase (iNOS), TNF, 
IL-6, and COX-2 expression were investigated.
MaTerials anD MeThODs
animals
We used male and female Tlr2/4−/− mice and their wild-type (WT) 
littermates, which were backcrossed for nine times to the C57/
BL6 background (20–28 g) (17). All mice had access to water and 
food ad libitum. All experiments were performed in agreement 
with the guidelines of the animal care institutions of the Technical 
University of Munich and the University of Munich and approved 
by the Government of Upper Bavaria (protocol number 118/05). 
The following group sizes were used:
– Brain water: n = 7–8 animals per group, two groups
– Contusion volume: n = 5 animals per group, three groups
– PCR: n = 5 animals per group, seven groups.
anesthesia
Anesthesia was induced in an isoflurane chamber (4%) within 
2 min and was maintained by 2% isoflurane, 30% O2, and 68% 
N2O applied by a facemask. A feedback-controlled heating pad 
(FHC, Bowdoinham, ME, USA) maintained body temperature 
at 37°C.
controlled cortical impact
After the animals were anesthetized and fixed in a stereotactic 
frame by a nose clamp, a median incision of the scalp and a 
craniotomy of 4  mm ×  4  mm were performed postero-lateral 
to the bregma without lacerating the dura mater. CCI (Mouse-
Katjuscha 2000, L. Kopacz, University of Mainz, Germany) was 
performed for 150  ms perpendicular to the dura mater with a 
diameter of 3 mm, a velocity of 8 m/s, and a dislocation of the 
brain of 1 mm as described earlier; in previous works, physiologi-
cal measurements did not show any side effects such as decrease 
oxygen saturation or apnea (18, 19). Moreover, no animal in this 
series died before finishing the experiments. The craniotomy was 
closed by adapting the bone flap with tissue glue (Histoacryl®, 
Braun-Melsungen, Melsungen, Germany), and the scalp was 
sutured with non-resorbable suture. Mice were kept in an incuba-
tor heated to 35°C until recovery of spontaneous motor activity. 
The procedure was performed under sterile conditions to prevent 
bacterial contamination.
Determination of Brain Water content 
(BWc)
Twenty-four hours after CCI, mice were sacrificed under deep 
isoflurane anesthesia, by cervical dislocation and brains were 
removed. Olfactory bulb, cerebellum, and brain stem were 
removed, and hemispheres were divided with a brain matrix 
(Kent Scientific, USA). The brains were immediately weighted in 
wet state (ww), dried at 110°C for 24 h, and dry weight (dw) was 
measured. BWC was then calculated by the following formula: 
(ww − dw)/ww × 100.
Quantification of contusion Volume
Mice underwent cervical dislocation 15 min or 24 h after trauma 
under deep isoflurane anesthesia. Brains were removed, instantly 
frozen in dry ice, and kept at −20°C until further analysis. Coronal 
frozen sections with a thickness of 10  µm were sliced every 
500 µm with a cryostat (CryoStar HM 560, Microm, Germany) 
and Nissl stained (20). The contused area was then measured on 
the digital photographs using standard image analysis software 
TaBle 1 | Used primers for the PCR.
gene amplicon size (bp) assay iD
Glyeraldehyde-3-phosphate 107 Mm99999915_g1
Tumor necrosis factor 81 Mm00443258_m1
Interleukin-1β 99 Mm99999061_mH
Interleukin-6 67 Mm01210732_g1
Prostaglandin-endoperoxide  
synthase 2 (COX-2)
80 Mm00478374_m1
Inducible nitric oxide synthetase 70 Mm00440485_m1
High-mobility group box 1 158 Mm00849805_gH
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(Olympus DP-soft, Germany) by an investigator blinded to the 
genotype of the animals. Contusion volume (V) was calculated as 
described earlier (21).
reverse Transcriptase real-time 
Polymerase chain reaction (rT-qPcr)
15 min, 3 h, 6 h, 12 h, and 24 h after CCI, mice (five animals 
per time point) were re-anesthetized with isoflurane, sacri-
ficed, and brains were removed under sterile conditions. This 
was also done in non-injured mice and in another group 6 h 
after sham-operation, which had undergone anesthesia, scalp, 
and skull opening as well as skull and scalp closing without 
applying CCI.
Total RNA from whole murine brains was then isolated with the 
guanidinum thiocyanate method (22). Reverse transcription was 
performed using “High Capacity cDNA Reverse Transcription 
Kit” (Applied Biosystems, Darmstadt, Germany). 25  µl RNA 
aliquots were used in 50 µl reaction mixtures containing 5 µl 10× 
reverse transcriptase buffer, 5 µl 10× random hexamer primers, 
2.5 µl “Multi Scribe Reverse Transcriptase” (50 U/μl), 2 µl 25× 
dNTP mixture, and 10.5 µl nuclease-free water.
For quantitative RT-PCR, 16.625 ng of single-stranded cDNA 
was mixed with supplied 2× TaqMan® Gene Expression Master 
Mix (Applied Biosystems, Carlsbad, CA, USA) and 2.22  µl 
TaqMan® Gene Expression Assay to a final volume of 33.625 µl. 
The following TaqMan® Gene Expression Assays were used for 
this investigation (Table 1). For amplification, 10 µl of the reac-
tion mixture was used in a 384-well optical reaction plate. Each 
sample underwent 40 cycles of amplification (15  s 95°C, 60  s 
60°C) on an Applied Biosystems 7900HT Fast Real-Time PCR 
System using absolute quantification. The results were adjusted 
to the housekeeping gene GAPDH. Relative quotients (RQ) of 
gene expression comparing control mice with operated mice at 
different time points were calculated with Microsoft Excel. RQ 
results were analyzed using the GraphPad Prism 4.05 (GraphPad 
Software, San Diego, CA, USA).
experimental Design
At first, we investigated post-traumatic brain edema forma-
tion (n = 7–8 per group) and secondary contusion expansion 
(n =  5 per group) 24  h after CCI in Tlr2/4−/− and WT mice. 
For measuring secondary contusion expansion, another five 
animals were sacrificed 15 min after CCI to measure primary 
contusion volume. In these experiments, all WT animals were 
randomly assigned to each group, and the investigator who 
performed animal surgery was blinded in terms of the strain’s 
genetic characteristics.
For investigation of mRNA expression in WT mice, we exam-
ined seven groups each consisting five animals: one group of 
non-injured mice, one group sacrificed 6 h after sham-operation, 
and five other groups in which brains were removed 15 min, 3 h, 
6 h, 12 h, or 24 h after CCI. All animals were randomly assigned 
to the respective group.
For investigation of mRNA expression in TLR2/4 double-
deficient animals, we examined five groups each consisting of 
five animals: one group of animals 6 h after sham-operation, and 
four other groups in which brains were removed 3, 6, 12, and 
24 h after CCI. Again, all animals were randomly assigned to the 
respective group.
statistical analysis
Measurements over time (mRNA expression) were tested versus 
baseline with Friedman Repeated Measures analysis of variance 
(ANOVA) on Ranks followed by Student–Newman–Keuls All 
Pairwise Multiple Comparison Procedure as post hoc test.
Differences between groups were tested by the Kruskal–
Wallis test for non-parametric one-way ANOVA followed by 
Student–Newman–Keuls All Pairwise Multiple Comparison 
Procedure or Dunn’s test as post hoc test. Differences between 
two groups were tested using the Mann–Whitney–Wilcoxon 
test for multiple comparisons on ranks for independent 
samples (SigmaStat 3.5, Jandel Scientific, Erkrath, Germany). 
p < 0.05 was considered significant. All results are presented as 
mean ± SEM.
resUlTs
Brain Water content
In WT mice, TBI significantly increased BWC of the traumatized 
right hemisphere to 80.9 ±  0.5% (p <  0.001), while the BWC 
of the contralateral hemisphere did not change significantly 
compared to non-traumatized animals (78.5 ± 0.2%) (data not 
shown). In Tlr2/4−/− animals, post-traumatic BWC was similar 
to WT mice in the traumatized (80.3 ± 0.2% in TLR2/4−/− ver-
sus 80.9 ±  0.5% in WT animals; p =  0.573) as well as in the 
non-traumatized contralateral hemisphere (78.3  ±  0.4% in 
TLR2/4−/− versus 78.5 ± 0.2% in WT animals; not significant). 
Thus, post-traumatic BWC was not significantly altered in 
Tlr2/4−/− animals.
contusion Volume 24 h after cci
Tlr2/4−/− animals as well as WT mice showed a significant increase 
of contusion volume 24 h after trauma compared to the primary 
brain damage in mice, which were sacrificed 15 min after CCI 
(22.0 ± 0.6 mm3 15 min after trauma versus 33.5 ± 0.8 mm3 in 
WT mice and 29.7 ± 0.7 mm3 in TLR2/4−/− animals; p < 0.001). 
Contusion volume 24  h after trauma was significantly smaller 
in Tlr2/4−/− mice (29.7 ±  0.7  mm3) compared to WT animals 
(33.5 ±  0.8  mm3, p <  0.01), which represents a reduction of 
secondary contusion growth by 34% (Figure 1).
FigUre 1 | Contusion volume 24 h after controlled cortical impact in 
wild-type (WT) and Tlr2/4−/− mice. Contusion volume is significantly reduced 
in Tlr2/4−/− mice (mean ± SEM; n = 5 animals per group; p < 0.01).
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rna expression
Reverse-transcriptase real-time polymerase chain reaction 
analy sis demonstrated a differential expression TLR2 and 4 
and IL-1β, iNOS, TNF-α, IL-6, COX-2, and HMGB1. Increased 
expression of IL-1β was observed from 3  h post-CCI with a 
maximum increase 12  h (Tlr2/4−/−) and 24  h (WT) after TBI. 
Six hours after CCI, we recognized a 1.8-fold higher expression 
of IL-1β mRNA in Tlr2/4−/− mice compared to WT animals 
(p < 0.05, Figure 2A).
In respect to the expression of iNOS mRNA, no significant 
difference between Tlr2/4−/− and WT mice was observed. But, in 
Tlr2/4−/− as well as WT mice a significant (2.3-fold) increase of 
iNOS expression levels was observed already at 12 h after experi-
mental TBI and was maximal (5.7-fold, WT; 3.1-fold, TLR2/4−/−) 
at the 24 h post-CCI time point (p < 0.05, Figure 2B).
Expression of TNF mRNA was increased already 3  h after 
trauma and maximal (137-fold, WT; 141-fold, TLR2/4−/−) 6  h 
after CCI (Figure 2C). It did not differ in Tlr2/4−/− and WT mice 
to a significant degree at any time point. IL-6 mRNA accumula-
tion did also not differ significantly in Tlr2/4−/− as compared to 
WT brains at any time point as well.
Expression of IL-6 mRNA was already increased 3  h after 
CCI with a maximum of 799-fold (WT) and 513-fold (Tlr2/4−/−) 
increase 24 h after trauma as compared to controls (Figure 2D).
COX-2 mRNA expression increased 3 h post-CCI and reached 
maxima of 3.6- and 5.3-fold 3 and 6 h after trauma, respectively, 
without significant differences between the groups (Figure 2E).
High-mobility group box 1 mRNA expression was increased 
4.9-fold at the 15 min time point after experimental TBI already 
but declined toward 12 h post-CCI (Figure 2F). Moreover, 6 h 
after trauma, we observed a 2.3-fold higher HMGB1 mRNA 
expression in WT compared with Tlr2/4−/− animals (p < 0.05).
We observed significantly increased IL-1β, TNF, and IL-6 
mRNA expression in sham-operated animals. Still, the mRNA 
levels remained far below the levels in mice 6 h after CCI. No 
differences in mRNA expression of iNOS, COX-2, and HMGB1 
were observed in sham-operated mice compared to non-oper-
ated animals and compared to animals sacrificed 15 min after 
CCI (Figure  2). Although differences did not reach statistical 
significance, we observed a robust trend toward a higher expres-
sion of IL-1β and a lower expression of iNOS, IL-6, COX-2, and 
HMGB1 in Tlr2/4−/− as compared to WT mice, especially 6  h 
after CCI.
DiscUssiOn
Secondary brain damage is the parenchymal damage that 
develops on top of the primary tissue damage. This study shows 
that the expansion of the contused brain volume from 22.0 to 
33.5  mm3 (p <  0.001) was apparent within 24  h upon trauma, 
i.e., a secondary growth of contusion of 52% as previously shown 
(18). The central finding of this study is that secondary contusion 
growth is reduced by 34% in Tlr2/4−/− mice while post-traumatic 
brain edema formation was not affected. Although the involved 
mechanisms are complex and interacting, we interpret our find-
ing that TLR2 and 4 might promote TBI-mediated tissue damage 
by triggering an enhanced neuroinflammatory response resulting 
in further cell death.
TLR2 as well as TLR4 are expressed on microglia and astro-
cytes (11). After acute brain injury, an upregulation and/or release 
of endogenous TLR ligands including fibrinogen, monosodium 
urate, HSP70, and heparan sulfate fragments has been observed 
in both humans and animal models (23, 24). Consequently, we 
and others speculate that endogenous danger signals released 
from dying cells or extracellular matrix upon acute brain injury 
might be recognized by TLR2 and TLR4 to initiate inflammatory 
responses that aggravate secondary brain damage and increase 
morbidity after TBI (8).
A reduced inflammatory response after TBI has been observed 
in Myd88−/− mice, lacking expression of a key adapter molecule 
mediating most intracellular signaling of TLRs. This Myd88−/− 
phenotype was associated with an attenuation of parenchymal 
damage after brain cold injury (9). Yet, in such a model, the lack 
of TLR2 and TLR4 expression by Tlr2/4−/− mice did not impact on 
neuroinflammation since their phenotype as compared to that of 
WT animals was unremarkable. Cold injury models, though, do 
not mirror clinical reality appropriately; therefore, these results 
need to be interpreted carefully.
Specific substances released by apoptotic and necrotic cells 
such as uric acid, HMGB1, and endogenous nucleic acids have 
been implicated as endogenous immunostimulants (25, 26). Due 
to parenchymal disruption, the destruction of extracellular matrix 
causes liberation of heparan sulfate, fibrinogen, or hyaluronan 
fragments, which have been reported to activate TLR4 (13–15). 
Accordingly, danger signals such as HMGB1 or hyaluronan frag-
ments activate TLR2 (14, 15). TLR4 recognizes LPS, a component 
of the outer cell wall of Gram-negative bacteria and endogenous 
substances such as those listed above (13). Lack of TLR2 and 4 
does therefore not allow large parts of pro-inflammatory reaction, 
which seems to have neuroprotective effects. This is also well in 
accordance with other data on experimental TBI showing TLR2, 
TLR4, HSP70, and Myd88 to accumulate in lesioned regions 
but also the subcortical white matter (27). Pro-inflammatory 
FigUre 2 | Expression of mRNA after different time points following trauma in wild-type (WT) (black) and Tlr2/4−/− mice (white). Values are expressed relatively to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene (mean ± SEM; n = 5 animals per group). (a) Interleukin (IL)-1beta. (B) Inducible nitric 
oxide synthetase (iNOS). (c) TNF. (D) IL-6. (e) COX-2. (F) High-mobility group box (1HMGB1).
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mediators such as cytokines drive CNS inflammation by inducing 
chemokines and adhesion molecules, stimulating immune cells 
and endogenous glial cells, and recruiting immune cells into the 
cerebral parenchyma (28).
The observed increase in IL-1β expression is well in accord-
ance with other investigation on spinal cord injury indicating 
an upregulation of IL-1β in TLR4−/− mice (29). In their discus-
sion, Impellizzeri and colleagues argued that the also increased 
“NF-KB has an important function in the regulation of many 
genes responsible for the generation of mediators or proteins 
in secondary inflammation associated with spinal cord injury 
such as IL-1β, TNF-α, iNOS” as already shown by Verma in 2004 
(29, 30). Moreover, Impellizzeri et al. also showed an increase in 
neutrophil infiltration, which they explained by “pro-inflamma-
tory cytokines (coordinating) other immune cells, attracting them 
to the site of damage, amplifying it until the insult is eliminated 
or dampened by immune-suppressing feedback mechanisms as 
already demonstrated” by Buchanan et al. in 2010 (29, 31). In the 
6Krieg et al. TLR2 and 4 Deficiency in TBI
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CNS, IL-1β reduces glutamate release, induces expression levels 
of growth factors and modulates neuronal responses to NMDA 
and glycine (28). After CNS injury, IL-1β is immediately released 
from microglia and astrocytes (32).
Nitric oxide (NO) affects neurodegeneration and aggravates 
secondary brain damage after TBI and focal cerebral ischemia 
(33). Moreover, NO is produced by glial iNOS of which is 
known to be induced not only by IL-1β but also by IFN-α 
and TNF (6). In a model of focal cerebral ischemia, iNOS was 
reduced in Tlr4−/− mice 24  h after ischemia (33). Like IL-1β, 
TNF is known to be increased after parenchymal cerebral 
injury as well (32). TNF involvement has been implicated 
in various experimental models of TBI as well as in human 
brain injury where it was shown to be released (4, 34, 35). In 
these studies, TNF levels were increased particularly within 
the brain parenchyma rapidly after injury, and its level was 
associated with the neurological deficit in rodents subjected to 
experimental TBI (3, 4). We confirmed this rapid upregulation 
of TNF expression (Figure 2) suggesting that it is released by 
resident cells of the brain parenchyma rather than by blood-
borne leukocytes, which invade the brain later than 12 h after 
TBI (36). We consequently conclude that TLR2 and 4 are not 
involved in TNF induction during TBI, although TNF itself 
has been shown to be crucially involved in microglia activation 
following TBI (37).
After brain injury, increased levels of IL-6 and its receptor 
have been measured in the cerebral parenchyma in a range of 
animal models, in human cerebrospinal fluid, and in the serum 
of patients after TBI (34). Under physiological circumstances, 
expression of IL-6 mRNA in the brain is very low, although, 
in a large number of human CNS disorders, IL-6 expression is 
severely increased. The main reason is supposed to be induction 
by central production of inflammatory cytokines. For instance, 
IL-6 can be induced by IL-1, transforming growth factor-b, TNF, 
and prostaglandins (6). Thus, IL-6 mRNA expression does not 
have to be induced through direct cellular activation of TLRs, but 
can also be activated indirectly through the mentioned media-
tors. IL-6 was also shown to be highly upregulated after trauma 
in mice (9).
Another important but different group of mediators of inflam-
matory reaction are prostaglandins that are generated by COX 
from arachidonic acid and prostaglandin synthase enzymes. 
As COX-2 is only stimulated as a response to inflammatory 
mediators, it served as a measure for prostaglandin metabolism 
in this study. Although prostaglandins are typically known to 
be powerful pro-inflammatory molecules, they also include 
anti-inflammatory properties under special conditions. Post-
traumatic pharmaceutical inhibition of COX-2 in rats showed 
improved neurological outcome (38).
Principally, high-mobility group proteins are chromosomal 
proteins that are involved in transcription as well as recombina-
tion and replication of DNA. In addition, HMGB1 is known to 
be liberated by brain damage after which it was proofed to have 
extracellular activity by acting as a chemokine and therefore 
attracting inflammatory cells. It serves as a novel pro-inflamma-
tory cytokine-like factor, which connects excitotoxicity-induced 
acute damage processes and delayed inflammatory action in 
the post-ischemic brain (25, 26, 39). After acute TBI, HMGB1 
was reported to be upregulated as well (9) and was implicated 
as TLR2 and 4 ligand qualifying it as potential key mediator 
for the induction of neuroinflammation (14). According to 
our data, HMGB1 is involved in the pathophysiology of TBI, 
and its release is regulated by TLR2 or 4 activation. We may 
speculate that the lack of inflammatory cytokine upregulation in 
Tlr2/4−/− mice may be one mechanism responsible for attenuated 
neuronal damage.
Mechanisms, which control the different cytokines, are often 
linked; TNF stimulates expression of IL-1 and IL-6, whereas IL-1 
can induce both IL-6 and TNF. So, after brain damage, primary 
upregulation of cytokines causes infiltration of further inflam-
matory mediators to the contusion site, and further cytokine 
signaling results. Especially HMGB1 seems to be one of the 
most crucial factors why TLR2/4 double-deficiency causes less 
neuronal cell death. Whether HMGB1 acts as an endogenous 
ligand that activates TLR2 or 4 signaling in damaged brain 
tissue or HMGB1 is released through TLR2/4 activation needs 
further investigation. It might use both possibilities as part of an 
amplification pathway.
Whether TLR2 or 4, or the combination of both is involved in 
the development of secondary brain damage, cannot be answered 
by this study. Conversely, the study by Yu and Zha tells us that 
TLR2 is involved in the aggravation of secondary brain damage 
including a reduction of TNF-α, IL-1β, and IL-6 in Tlr2−/− 
compared to WT mice (40). Likewise, other groups also found 
reduced focal lesions in Tlr4−/− mice not only after experimental 
stroke but also after experimental TBI (41, 42).
limitations
Nonetheless, the investigation of later time point, such as 7 or 
14 days after trauma, should also be considered in consecutive 
studies to analyze not only short- but also long-term effects of 
these immunological alterations (43, 44). In such long-term 
series, additional behavioral outcomes should also be included 
which were also not subject to this study.
Moreover, there are always limitations when intending to 
transfer rodent data to human patients. One major difference 
is that TBI causes additional issues in humans, which are not 
present in rodent, e.g., growth or secondary development of 
intraperanchymal hematomas. Accordingly, we are only able to 
investigate some issues of human TBI in such models rather than 
mimicking the whole pathophysiological process.
As mentioned earlier, both, male and female mice, were 
enrolled in this study. Since there are severe differences between 
genders concerning TBI outcome in rodents, the distribution 
among groups was homogenous.
As another limitation, nonetheless, this study only examined 
the gene expression. A follow-up study investigating the protein 
expression should be performed.
cOnclUsiOn
Taken together, this study shows that TLR2 and 4 might drive 
neuroinflammation and are involved in the development of sec-
ondary brain damage after experimental TBI. Unfortunately, the 
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current results do not allow us to differentiate between the effects 
of TLR2, TLR4, or the combination of both.
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